Inflammatory Bowel Diseases Clinical Trial
Official title:
Effect of Semi-vegetarian Diet in Inflammatory Bowel Disease Patients With Clinical Remission
Verified date | May 2022 |
Source | Mahidol University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In the 21st century, the incidence of inflammatory bowel disease (IBD) globally increases. Higher incidence of IBD development may implicate that environmental factors played essential roles in IBD pathogenesis. One of the environmental factors is a westernized diet that contains a high amount of animal protein and a low amount of dietary fiber. This kind of diet can lead to gut microbial dysbiosis and increase susceptibility to IBD. A microbial dysbiosis pattern in IBD is a decrease in microbial diversity and the inversed ratio of local protective and pathologic bacteria. High animal protein was associated with an increased risk of IBD and increased risk of disease relapse meanwhile dietary fiber was associated with IBD risk reduction. A semi-vegetarian diet is a diet with high fiber and low red meat and processed food that may reduce inflammatory activity in IBD. The study in the semi-vegetarian diet in IBD activity is still limited. This study aimed to evaluate a semi-vegetarian diet's effect in maintaining IBD remission in disease quiescence patients.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 1, 2021 |
Est. primary completion date | October 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients with Crohn's disease or Ulcerative colitis 2. Age = 18 years old 3. Disease in remission at least 2weeks by following criteria Crohn's disease: Crohn's Disease Activity Index(CDAI) < 150 Ulcerative colitis: Mayo Ulcerative Colitis Subscore = 2 4. Prednisolone = 15 mg/day for at least 1 month 5. Stable immunomodulator dosage at least 1 month 6. Stable biologic agent at least 2 months Exclusion Criteria: 1. Patients with Ulcerative colitis with a history of proctocolectomy 2. Patients with Crohn's disease with bowel stricture 3. Patients with recently antibiotic usage within 1 month 4. Pregnant patients |
Country | Name | City | State |
---|---|---|---|
Thailand | Gastroenterology division, Faculty of Medicine, Siriraj Hospital, Mahidol University | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of participants with clinical relapses | Effect of semi-vegetarian food consumption on the rate of participants with clinical relapses assessed by Crohn's disease activity index for Crohn's disease and the clinical Mayo Score or partial Mayo Score for ulcerative colitis. The Crohn's disease activity index ranges from 0 to 1100, a higher score means a worse outcome, and clinical relapse is defined if the score is at least 150 points. The clinical Mayo Score for ulcerative colitis ranges from 0 to 9, a higher score means a worse outcome, and clinical relapse is defined if the score is at least 2 points. | 1 year | |
Secondary | C-Reactive Protein (CRP) | Effect of semi-vegetarian food consumption on inflammatory markers levels including serum CRP | 1 year | |
Secondary | fecal calprotectin level | Effect of semi-vegetarian food consumption on inflammatory markers levels including fecal calprotectin level | 1 year | |
Secondary | Fecal microbiota | Effect of semi-vegetarian food consumption on changing of fecal microbiota composition and diversity (Shannon's diversity index) | 1 year | |
Secondary | Quality of life score of SIBDQ | Effect of semi-vegetarian food consumption on quality of life: SIBDQ | 1 year | |
Secondary | Quality of life score of EQ5D3L | Effect of semi-vegetarian food consumption on quality of life: EQ5D3L | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02874365 -
Intestinal Stem Cells Characterization
|
N/A |